GraftSolutions develops surgical devices that improve coronary artery bypass grafting outcomes. Its VIOLA™ system enables clam‑less proximal aortic anastomosis, eliminating the need for aortic clamps and reducing stroke and delirium risk, while the VEST™ external sleeve reinforces saphenous vein grafts to lower intimal hyperplasia and re‑vascularization rates. Both products are clinically validated and aim to extend graft durability and lower overall care costs for cardiac surgery programs.
Funding
Funding not disclosed
Founders
Product
Problem
Coronary artery bypass grafting (CABG) suffers from two major issues: limited long‑term patency of saphenous vein grafts and the risk of neurological complications caused by aortic clamping during proximal anastomosis.
Solution
GraftSolutions offers two complementary devices to address these challenges. The VIOLA™ system enables clampless proximal anastomosis by providing a built‑in punching and sealing mechanism that creates a hemostatic connection to the aorta without a clamp, thereby eliminating intra‑operative stroke and delirium risk. The VEST™ external support sleeve encircles saphenous vein grafts, delivering biomechanical reinforcement that reduces intimal hyperplasia, lumen irregularities, and subsequent ischemic revascularization, as demonstrated in randomized trials and real‑world data. Together, the devices improve graft durability and patient outcomes while lowering the overall cost of care for hospitals.
Target Audience
Primary customers are cardiac surgeons and cardiovascular surgery departments performing coronary bypass procedures in hospitals and specialized cardiac centers.
Features
- VIOLA™ clampless anastomosis device with integrated punching and sealing for reliable aortic connections
- Eliminates need for aortic clamps, reducing peri‑operative stroke and postoperative delirium to near‑zero rates
- VEST™ external stent sleeve that provides uniform external support to saphenous vein grafts
- Clinically proven reduction in intimal hyperplasia and lumen irregularities (P < 0.001) and lower rates of ischemic-driven revascularization
- Compatible with standard CABG workflow and reusable across multiple anastomoses in a single procedure
- Supported by multicenter randomized controlled trials and ongoing real‑world performance data